

Literatur

1. Raab O. Ueber die Wirkung fluorescirender Stoffe auf Infusorien. *Z Biol* 1900;39:524-46
2. Ackroyd R et al. The history of photodetection and photodynamic therapy. *Photochem Photobiol* 2001;74:656-69
3. Taub AF. Photodynamic therapy in dermatology: History and horizons. *J Drugs Dermatol* 2004;3 (Suppl 1):S8-25
4. Fitzgerald F. *Photodynamic therapy (PDT): Principles, mechanisms and applications*. New York: Nova Science; 2017
5. Dolmans DEJGJ et al. Photodynamic therapy for cancer. *Nat Rev Cancer* 2003;3:380-7
6. Ozog DM et al. Photodynamic therapy: a clinical consensus guide. *Dermatol Surg* 2016;42:804-27
7. Kalka K et al. Photodynamic therapy in dermatology. *J Am Acad Dermatol* 2000;42:389-413
8. Leman JA et al. Photodynamic therapy: applications in dermatology. *Expert Opin Biol Ther* 2002;2:45-53
9. Kennedy JC et al. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. *J Photochem Photobiol B Biol* 1990;6:143-8
10. Iinuma S et al. A mechanistic study of cellular photodestruction with 5-aminolevulinic acid-induced porphyrin. *Br J Cancer* 1994;70:21-8
11. Divaris DX et al. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. *Am J Pathol* 1990;136:891-7
12. Meierhofer C et al. The impact of occlusive vs non-occlusive application of 5-aminolevulinic acid (BF-200 ALA) on the efficacy and tolerability of photodynamic therapy for actinic keratosis on the scalp and face: A prospective within-patient comparison trial. *Photodermatol Photoimmunol Photomed* 2021;37:56-62
13. Morton CA et al. European dermatology forum guidelines on topical photodynamic therapy 2019. Part 1: treatment delivery and established indications—actinic keratoses, Bowen's disease and basal cell carcinomas. *J Eur Acad Dermatol Venereol* 2019;33:2225-38
14. Agostinis P et al. Photodynamic therapy of cancer: An update. *CA Cancer J Clin* 2011;61:250-81
15. Kwiatkowski S et al. Photodynamic therapy—Mechanisms, photosensitizers and combinations. *Biomed Pharmacother* 2018;106:1098-107
16. Morton CA et al. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. *J Eur Acad Dermatol Venereol* 2015;29:1718-23
17. Wiegell SR et al. Daylight photodynamic therapy for actinic keratosis: an international consensus. *J Eur Acad Dermatol Venereol* 2012;26:673-9
18. Nguyen M et al. Clinical utility of daylight photodynamic therapy in the treatment of actinic keratosis—A review of the literature. *Clin Cosmet Investig Dermatol* 2019;12:427-35
19. Morton CA et al. Daylight photodynamic therapy for actinic keratoses. *Am J Clin Dermatol* 2018;19:647-56
20. Spring BQ et al. The role of photodynamic therapy in overcoming cancer drug resistance. *Photochem Photobiol Sci* 2015;14:1476-91
21. Wang B et al. Gain with no pain? Pain management in dermatological photodynamic therapy. *Br J Dermatol* 2017;177:656-65
22. Babes A et al. Photosensitization in porphyrias and photodynamic therapy involves TRPA1 and TRPV1. *J Neurosci* 2016;36:5264-78
23. Silic K et al. Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region—A randomized controlled comparison study. *Photodiagnosis Photodyn Ther* 2022;40:103190
24. Ang JM et al. Photodynamic therapy and pain: a systematic review. *Photodiagnosis Photodyn Ther* 2017;19:308-44
25. Barge J et al. Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives. *Photodiagnosis Photodyn Ther* 2013;10:683-93
26. Piffaretti F et al. Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. *Dermatology* 2013;227:214-25
27. Boen M et al. The role of photodynamic therapy in acne: an evidence-based review. *Am J Clin Dermatol* 2017;18:311-21
28. Dirschka T et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratoses: results of a multicentre, randomized, observer-blind phase III study in comparison with registered methyl-5-aminolevulinate cream and placebo. *Br J Dermatol* 2012;166:137-46
29. Szeimies RM et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. *Br J Dermatol* 2010;163:386-94
30. Morton CA et al. Intraindividual, right-left comparison of topical methyl aminolevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. *Br J Dermatol* 2006;155:1029-36
31. Gupta AK et al. Interventions for actinic keratoses. *Cochrane Database Syst Rev* 2012;12:CD4415
32. Szeimies RM et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. *J Am Acad Dermatol* 2002;47:258-62
33. Freeman M et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study. *J Dermatolog Treat* 2003;14:99-106
34. Smith S et al. Short incubation PDT versus 5-FU in treating AK. *J Drugs Dermatol* 2003;2:629-35
35. Jeffes EW et al. Photodynamic therapy of AK with topical aminolevulinic acid hydrochloride and fluorescent blue light. *J Am Acad Dermatol* 2001;45:96-104
36. Tarstedt M et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. *Acta Derm Venereol* 2005;85:424-8
37. Pariser DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial. *J Am Acad Dermatol* 2003;48:227-232

38. Wiegell SR et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blind study. *Br J Dermatol* 2008;158:740-6
39. Wiegell SR et al. A randomized, multicentre study of directed daylight exposure times of 1 1/2 vs. 2 1/2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. *Br J Dermatol* 2011;164:1083-90
40. Wiegell SR et al. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp—a randomized multicentre study. *Br J Dermatol* 2012;166:1327-32
41. Radakovic S et al. 5-Aminolevulinic acid patch (Alacare) photodynamic therapy for actinic cheilitis: data from a prospective 12-month follow-up study on 21 patients. *J Eur Acad Dermatol Venereol* 2022;34:2011-15
42. Radakovic S et al. 5-aminolaevulinic acid patch-photodynamic therapy in the treatment of actinic cheilitis. *Photodermatol Photoimmunol Photomed* 2017;33:306-10
43. Bath-Hextall FJ et al. Interventions for cutaneous Bowen's disease. *Cochrane Database Syst Rev* 2013;6:CD7281
44. Cox NH et al. Guidelines for management of Bowen's disease: 2006 update. *Br J Dermatol* 2007;156:11-21
45. Morton CA et al. A randomized, placebo-controlled, European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in subjects with Bowen's disease. *Arch Dermatol* 2006;142:729-35
46. Truchuelo M et al. Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions. *J Eur Acad Dermatol Venereol* 2012;26:868-74
47. Cavicchini S et al. Long-term follow-up of methyl aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease. *Int J Dermatol* 2011;50:1002-5
48. Zhao B et al. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. *Expert Rev Anticancer Ther* 2010;10:1797-1809
49. Salim A et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. *Br J Dermatol* 2003;148:539-43
50. Patel GK et al. Imiquimod 5 % cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomised, double-blind placebo-controlled trial. *J Am Acad Dermatol* 2006;54:1025-32
51. Sotiriou E et al. Treatment of giant Bowen's disease with sequential use of photodynamic therapy and imiquimod cream. *Photodermatol Photoimmunol Photomed* 2011;27:164-6
52. Bhatta AK et al. Therapeutic effect of imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma. *Photodiagnosis Photodyn Ther* 2018;23:273-80
53. Vinciullo C et al. Photodynamic therapy with topical methyl aminolaevulinate for "difficult-to-treat" basal cell carcinoma. *Br J Dermatol* 2005;152:765-72
54. Gerritsen MJP et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. *Dermatology* 2009;218:193-202
55. Horn M et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. *Br J Dermatol* 2003;149:1242-9
56. Basset-Seguín N et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. *Eur J Dermatol* 2008;18:547-53
57. Szeimies R et al. A clinical study comparing methyl aminolevulinic acid photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. *J Eur Acad Dermatol Venereol* 2008;22:1302-11
58. Kuijpers D et al. Similar effectiveness of methyl aminolevulinic acid and 5-aminolevulinic acid in topical photodynamic therapy for nodular basal cell carcinoma. *J Drugs Dermatol* 2006;5:642-5
59. Christensen E et al. Pre-treatment deep curettage can significantly reduce tumour thickness in thick Basal cell carcinoma while maintaining a favourable cosmetic outcome when used in combination with topical photodynamic therapy. *J Skin Cancer* 2011;2011:240340
60. Rhodes LE et al. Photodynamic therapy using topical methyl aminolevulinic acid vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. *Arch Dermatol* 2004;140:17-23
61. Rhodes LE et al. Five year follow up of a randomized prospective trial of topical methyl aminolevulinic acid-photodynamic therapy versus surgery for nodular basal cell carcinoma. *Arch Dermatol* 2007;143:1131-6
62. Calzavara-Pinton PG et al. Methyl aminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. *Br J Dermatol* 2008;159:137-44
63. Morton CA et al. Photodynamic therapy for basal cell carcinoma—Effect of tumour thickness and duration of photosensitizer application on response. *Arch Dermatol* 1998;134:248-9
64. Stender IM et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. *Lancet* 2000;355:963-6
65. Schroeter CA et al. Successful treatment of periungual warts using photodynamic therapy: a pilot study. *J Eur Acad Dermatol Venereol* 2007;21:1170-4
66. Fernández-Guarino M et al. Treatment of recalcitrant viral warts with photodynamic therapy with mal and red light. *J Cosmet Dermatol Sci Appl* 2013;3:117-20
67. Radakovic S et al. Complete resolution of disseminated cutaneous warts after repetitive partial treatment with ALA PDT—indication of a PDT-induced systemic immune response. *J Dtsch Dermatol Ges* 2020;18:490-2
68. Radakovic S et al. Complete resolution of recalcitrant disseminated cutaneous warts after partial irradiation with photodynamic therapy via presumed stimulation of a systemic immune response: A retrospective analysis of 18 cases. *J Eur Acad Dermatol Venereol* 2023;37:e865-7
69. Wang XL et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. *Br J Dermatol* 2004;151:880-5

70. Chen K et al. Comparative study of photodynamic therapy vs. CO₂ laser vaporization in treatment of condylomata acuminata: A randomized clinical trial. *Br J Dermatol* 2007;156:516-20
71. Zakhary K et al. Applications of aminolevulinic acid-based photodynamic therapy in cosmetic facial plastic practices. *Facial Plast Surg* 2005;21:110-6
72. Uebelhoer NS et al. Photodynamic therapy for cosmetic applications. *Dermatol Ther* 2005;18:242-52
73. Morton CA et al. European dermatology forum guidelines on topical photodynamic therapy 2019. Part 2: emerging indications—field cancerization, photorejuvenation and inflammatory/ infective dermatoses. *J Eur Acad Dermatol Venereol* 2020;34:17–29
74. Issa M et al. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. *Dermatol Surg* 2010;36:39-48